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summary
Objective: To investigate the impact of knee osteoarthritis (OA) and/or knee pain on excess 
mortality.
Method: We analyzed data from 4,182 participants in a community-based prospective cohort 
study of African American and Caucasian men and women aged ≥45 years. Participants completed 
knee radiographs and questionnaires at baseline and at up to three follow-ups to determine knee 
OA (rOA), knee pain and covariate status. Mortality was determined through 2015. We used Cox 
proportional hazards regression with time-varying covariates (TVC) to estimate hazard ratios (HR) 
and 95% confidence intervals (CI). Additional analyses stratified by sex, race and age were carried 
out.
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Results: Median follow-up time was 14.6 years during which 1822 deaths occurred. Baseline 
knee radiographic osteoarthritis (rOA) was 27.7%, 38.8% at first follow-up, 52.6% at second 
follow-up and 61.9% at the third follow-up. Knee rOA with pain and knee pain alone were both 
associated with a >15% increase in premature all-cause mortality. In analyses stratified by sex, 
race and age, associations between knee pain, with or without knee rOA, and all-cause death were 
found among women, Caucasians, those≤65 years of age, and those with a body mass index (BMI)
≥30, with observed increased risks of death between 21% and 65%. We observed similar, 
somewhat attenuated, results for cardiovascular disease (CVD) deaths.
Conclusion: In models taking into account variables that change over time, individuals who had 
knee pain, alone or with knee rOA, had increased mortality. These effects were particularly strong 
among those obese. Effective interventions to reduce knee pain, particularly those including 
weight management and prevention of comorbidities, could reduce mortality.
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Introduction
Osteoarthritis (OA) is a well-described chronic joint disorder with clinical manifestations 
including substantial synovial joint pain, swelling and stiffness. It is the most common form 
of arthritis affecting nearly 31 million US adults1, with 13.7 million of those having 
symptomatic knee osteoarthritis2. The risk of developing knee OA by age 60 is 13.8%3 
which increases to 44.7% by age 854. This already considerable burden of OA is projected to 
continue to rise reflecting the aging population and an increase in OA risk factors such as 
obesity5.
Individuals with knee OA also experience increased rates of obesity and comorbidity, which 
can be as high as 85% in certain populations6,7. The links between OA and comorbidities are 
likely complex with evidence pointing to shared risk factors with common etiologic 
pathways including cardiovascular disease (CVD), type-two diabetes, and hypertension8–10. 
Further, OA can lead to significant functional limitations and depression which can lead to 
premature death11.
In recent years a number of studies have investigated the association between OA and 
premature mortality. A 2008 review suggested modest associations of OA with all-cause 
mortality but noted that technical shortcomings limited their conclusions, including differing 
study populations, small sample size and lack of inclusion of important covariates from 
some of the studies12. A more recent meta-analysis of nine studies reported no significant 
association between radiographic osteoarthritis (rOA) or symptomatic OA (SxOA) with 
mortality, however this study also did not differentiate between joint sites affected by OA, 
combining estimates for hand, knee, hip and spine OA13. Prospective studies addressing 
knee OA specifically as a risk factor for premature mortality have been equivocal with some 
reporting lower mortality among those with knee OA14–16 and others reporting higher 
mortality rates17–19. The conflicting results reported by these studies may be a result of 
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limitations including measurement of knee OA at a single baseline time point, lack of 
inclusion of important covariates, short duration of follow up, and/or small sample sizes.
Because of the inconsistent results to date, we sought to examine associations between knee 
rOA and/or knee pain and all-cause as well as CVD-specific death, independent of 
comorbidities, in a large community-based prospective cohort with nearly 25 years of 
follow-up and up to four repeated measurements of knee OA and covariates.
Methods
Study design and participants
The Johnston County Osteoarthritis Project (JoCoOA) is a community-based prospective 
cohort study of OA in North Carolina (NC). Details of JoCoOA have been previously 
described20,21. Briefly, we recruited African Americans (AA) and Caucasians from six 
townships in a rural NC county. Participants were English-speaking, noninstitutionalized 
civilians 45 years of age or older. We enrolled participants enrolled in two waves: the first 
from 1991 to 1997 and additional participants were enrolled from 2003 to 2004 (Appendix 
Fig. I). All participants completed informed consent forms. Interviewer-administered 
questionnaires, clinical examinations, and radiographs were completed for all participants at 
baseline and at up to three follow-up time points, the last of which was completed in 2015. 
Our analyses included individuals with at least one evaluable knee radiograph. The 
Institutional Review Boards at the University of North Carolina, Chapel Hill and the Centers 
for Disease Control and Prevention (CDC) in Atlanta, GA have continuously approved 
JoCoOA.
Knee pain and rOA definitions
Knee radiographs taken at baseline and available follow-up assessments were read paired for 
individual participants and were blinded to clinical status and participant identification. 
Interpretation was completed by a single radiologist (JBR) with high weighted inter-rater 
(kappa 0.86) and intra-rater reliability (kappa = 0.89)22. rOA was scored on the Kellgrene-
Lawrence (KL) scale from 0 to 423. A KL grade ≥2 was indicative of having knee rOA, with 
a comparison to those without knee rOA (i.e., KL grade <2). A KL grade ≥3 was indicative 
of having severe knee rOA, with a comparison to those without severe knee rOA (i.e., KL 
grade <3). Total knee replacement indicated in questionnaire data as being necessary 
because of OA was also classified as having knee rOA.
For knee pain assessments at baseline and all available follow-up time points, participants 
were asked about knee pain through the following question, “On most days, do you have 
pain, aching or stiffness in your [right/left] knee?” Participants with SxOA are a subset of 
individuals with knee rOA who responded yes to pain in the same knee that was classified 
rOA, with a comparison to those without knee SxOA (i.e., KL grade <2 and/or no knee pain, 
but can have one without the other).
We created a separate 4-level combined knee rOA/pain variable with mutually exclusive and 
exhaustive groupings to assess the independent effects of rOA status (rOA and knee pain) at 
each time point according to an individual’s worst knee on later risk of death. These 
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subgroups included: neither knee rOA nor knee pain in either knee (referent); knee rOA but 
no pain in the same joint; knee pain but no knee rOA in either joint; and both rOA and pain 
in the same knee (SxOA). Since our analysis was carried out on a person-level, there were 
some participants who had discordant joint knee rOA and pain (i.e., pain without rOA in one 
knee and rOA but no pain in the other knee) (Appendix Table I). We chose a conservative 
approach and included those participants in the knee rOA alone (without pain) group. A 
sensitivity analyses placing those participants instead in the knee pain alone group was 
conducted (Appendix Table II, Model 2).
To capture more precisely how knee rOA and/or pain affects mortality over 25 years, we 
were able to measure our knee rOA and pain predictors as they changed over time. Knee 
pain could alternate values from one time point to the next (i.e., have knee pain at one 
assessment but then have no knee pain at the next assessment). Knee rOA status could 
change at most once (i.e., from having no knee rOA at one assessment to having knee rOA at 
the next assessment); once a participant developed rOA, it could not be reversed.
Covariates
Covariate definitions and categories are summarized in Appendix Table III. Covariates 
which did not change over time, or changed at the same rate for all participants (i.e., age) 
included: enrollment wave (first or second), age (continuous), birth cohort (by decade), sex 
(male or female), race (AA or Caucasian), and self-reported formal education level (<12 yrs 
or ≥12 years). Covariates that could change over time but once developed could not be 
reversed included: hip rOA (KL grade ≥2), and self-reports of the following: knee injury 
(ever or never), smoking status (ever smoker or never smoker), alcohol use (ever user or 
never user) and self-reported comorbidities (yes or no) including cancer, liver disease, 
hypertension, diabetes or CVD. CVD was defined as reporting heart attack or other heart 
problems, stroke, circulation problems and/or use of CVD-specific medications. Also 
considered in models were time-varying covariates (TVC) which could alternate over time 
including body mass index (BMI) and self-reports of the following: use of non-steroidal 
anti-inflammatory drugs (NSAIDS) (yes or no), meeting the CDC guidelines for moderate/
vigorous physical activity (MVPA) (yes or no) and depressive symptoms. Depressive 
symptoms (depression) at the T0, T1 and T2 time points were defined as having a Center for 
Epidemiologic Studies Depression (CES-D) score of ≥16; at the T3 time point depression 
was defined as having a Patient Reported Outcomes Measurement Information System 
Depression (PROMIS-D) score of ≥1824.
Mortality
Vital status was determined for all participants at each follow-up assessment. Follow-up 
assessments took place from 1999 to 2004 (T1), 2006–2010 (T2) and 2013–2015 (T3). After 
the T3 follow-up was completed, individuals not known to be alive (died, moved out of the 
area or lost to follow-up) were submitted to the National Death Index (NDI) to ascertain date 
and cause of death through December 31, 2015. Additionally, known deaths not found 
through NDI records but confirmed through local vital records searches were also used. 
Using the International Classification of Diseases (ICD), CVD deaths were based on ICD-9 
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codes 393 to 398 and ICD-10 codes I-00 to I-99 listed on the death certificate as the 
underlying cause of death.
Statistical analysis
Descriptive statistics for covariates at baseline and at follow-up time points were computed. 
Continuous variables are presented as means and standard deviations (±SD) and categorical 
variables are presented as frequencies and percentages. All tests were two-sided and 
considered statistically significant at the 0.05 level. All analyses were conducted using the 
statistical software package SAS version 9.4 (SAS Institute Inc., Cary, NC).
Covariate information for at least one baseline measure was missing for 8.2% of the 
participants (Fig. 1). We used a multiple imputation (MI) model that included all baseline 
variables to impute missing baseline covariate values (all binary). Logistic regression was 
used to impute binary baseline covariates by fully conditional specification methods (FCS) 
which performs best for missing-at-random (MAR) patterns and a missing proportion of less 
than 50%25. Twenty imputed datasets were generated so that the number of imputations 
were at least equal to the percent of data missing one or more covariates26 (for more 
information see the Appendix). We used a last observation carried forward approach for 
binary missing data at subsequent follow-up assessments, where missing data ranged from 
0.1 to 0.3% (Appendix Table IV). Further, a complete-case sensitivity analysis was carried 
out (Appendix Table II, Model 3).
Kaplan–Meier methods27 were used to generate survival curves by baseline knee rOA and 
knee pain status, unadjusted and adjusted for baseline age and sex using inverse probability 
weights28. Cox proportional hazards regression27 with TVC changing with irregular 
intervals starting at baseline and at up to three follow-up assessments was used to estimate 
hazard ratios (HR) and 95% confidence intervals (CI) for all-cause and CVD-specific 
mortality in relation to knee rOA and knee pain measured over time. We examined whether 
the proportional hazards assumption was met using Schoenfeld residuals and testing their 
correlation with time, time2 and log(time) from Cox models27 and no evidence of violation 
of this assumption was found. While the subdistribution hazard approach is an arguably 
superior method to assess CVD-specific mortality29, these methods do not yet satisfactorily 
handle TVC30,31. Therefore, in order to use our covariates which change over time, CVD-
specific mortality analyses were modeled using the CVD-cause-specific hazard, treating 
non-CVD mortality competing events as censored observations. Separate analyses were 
carried out in each of the 20 imputed datasets, then estimated parameters from all imputed 
datasets were synthesized to generate a single estimate according to Rubin’s rules32. All 
models were stratified by decade birth cohort to account for calendar effects, which is 
recommended when following healthy people and when the calendar effect is likely to 
impact the outcome, mortality, as well as other risk factors33. Follow-up time was calculated 
from baseline assessment until death, or until censoring which took place when a participant 
was lost to follow-up or reached the end of study period (December 31, 2015).
Tests of interaction were performed and stratified analyses were conducted to describe 
associations between knee rOA status (rOA and/or knee pain) measures and all-cause or 
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CVD-specific survival by each of obesity (BMI<30 and BMI≥30), age group split at the 
median (<65 yrs and 65≥yrs), race (Caucasian and AA) and sex (male and female).
Sensitivity analyses: We carried out two additional sensitivity analyses. One excluded 
deaths occurring in the first year of follow-up after baseline and the second used only knee 
rOA measures from the baseline time point to assess whether study attrition may have 
affected our results (Appendix Table II, Models 4 & 5, respectively).
Results
The characteristics of JoCoOA cohort by study visit are reported in Table I. Mean age at 
baseline was 61.0 years, 63.2% were women, 34.3% AA and 75.0% were from the original 
study enrollment. There were 27.7% participants in our population with knee rOA at 
baseline, which increased to 38.8% at first follow-up, 52.6% at second follow-up and 61.9% 
by the third follow-up. Individuals with only a baseline assessment had higher frequencies of 
both knee rOA and knee pain (35.5% and 49.0%, respectively; data not shown). Similar to 
knee rOA, the percentage of obese individuals and those with diabetes increased over time. 
Through 2015, median follow-up time was 14.6 years and there were 1,822 deaths overall, 
677 (37.2%) of which resulted from CVD.
In models taking into consideration that covariates may change over time, we did not 
observe any increase in hazard for knee rOA when compared to those without rOA with 
respect to either all-cause or CVD-specific mortality (Table II). We observed a similar lack 
of association for individuals with severe knee rOA. However, we observed a 13% increased 
hazards for all-cause mortality among those with knee rOA who also had pain in the same 
joint (SxOA) when compared to those without SxOA (HR = 1.13, 95% CI = 1.01–1.26). 
Comparable associations with knee SxOA were observed for CVD-specific death, and 
tended to be somewhat stronger and which remained statistically significant after full 
covariate adjustment (including obesity, diabetes, and CVD) (HR = 1.19, 95% CI = 1.00–
1.43).
We present unadjusted and adjusted Kaplan–Meier survival curves for all-cause mortality 
according to the 4-level combined knee rOA/pain variable at baseline. Unadjusted survival 
estimates (Fig. 2(a)) indicate that those with knee SxOA had the worst survival, wherein we 
observed 50% survival at 15.3 years; median survival was 17.1 years among those with knee 
rOA alone and 20.2 years for those with knee pain alone. When taking age and sex into 
account, however, median survival times for those with SxOA (18.3 years) and knee rOA 
(21.6 years) increased, while median survival decreased for those with neither knee rOA nor 
knee pain (22.9 years) and for those with knee pain alone (19.0 years) (Fig. 2(b)).
Results from Cox proportional hazards models to estimate risk of death for time-varying 
values of the 4-level combined knee rOA/pain variable are presented in Table III. In 
covariate-adjusted models, compared to those with neither knee rOA nor knee pain, we 
observed an increased risk of all-cause mortality in participants with knee pain alone (HR = 
1.19, 95% CI = 1.04–1.35) as well as participants who have knee SxOA (HR = 1.17, 95% CI 
= 1.03–1.34). Similarly, we observed increased hazards for CVD-specific mortality among 
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those having both knee rOA and pain in the same knee, although the data indicated a lack of 
statistical significance after adjustment for covariates. Knee rOA without pain was not 
associated with an increase in either all-cause or CVD-specific mortality. Results from 
additional models that also included hip rOA as a covariate did not differ substantially (data 
not shown).
Results were not substantially different from analyses which placed discordant joint knee 
rOA and pain in the knee pain group instead of the knee rOA group, for analyses carried out 
on a complete-case dataset, analyses which excluded deaths occurring in the first year of 
follow-up after baseline, nor did results differ when assessing knee rOA and covariates 
measured only at baseline instead of TVC (Appendix Table II Models 2, 3, 4 & 5, 
respectively).
Stratified analyses
We examined the association between the 4-level combined knee rOA/pain variable and 
mortality stratified by obesity and demographics (Fig. 3). Covariate-adjusted HR estimates 
for all-cause mortality were increased 21–65% for knee pain with or without rOA among 
women, Caucasians, those under the age of 65 and those with a BMI≥30. For example, 
among those with a BMI≥30 we observed an increase in hazards for both knee pain alone 
(HR = 1.66, 95% CI = 1.31–2.10) and knee SxOA (HR = 1.47, 95% CI = 1.18–1.83), while 
we observed no association among those with a BMI<30 (interaction P-value<0.01). No 
other statistical interaction was observed. Similar results for risk of CVD-specific death 
among those having knee SxOA were observed.
Discussion
In this longitudinal community-based cohort of AA and Caucasian men and women we 
found that individuals with knee pain or painful knee rOA have an increased risk of death 
from all-causes. In stratified analyses, these associations were observed among those with a 
BMI≥30, and among those <65 years of age at baseline. We found no association, however, 
between radiographic knee OA alone (without pain) and risk of death due to either all-causes 
or CVD specifically.
Our results follow a similar pattern as those reported in a recent study, though our estimates 
were not of the same magnitude17. Kluzek et al. also reported no association with rOA 
without pain, but about a 50% increased risk of mortality with pain only and 97% increase 
with both. When we looked at categories of knee rOA and knee pain separately we found 
that our associations were limited to those with knee pain, though there were few individuals 
in our study with knee rOA who did not also have pain. The study by Kluzek et al. was 
limited to women who have more reported knee pain, whereas our study includes men and 
older individuals who have higher mortality rates, both of which may account for the smaller 
estimates.
Other studies have provided inconsistent reports of increased18, decreased14 and no15,16 risk 
of death with knee OA. Most of these studies did not distinguish between those with knee 
rOA and those with knee SxOA. Further, several studies used knee OA data extracted from 
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medical records14–16. These individuals would be more likely to be characterized as having 
knee SxOA rather than knee rOA alone since they were diagnosed with knee OA by a 
physician only after seeking medical care, presumably due to the presence of knee pain. One 
other study reported a nearly two-fold increased risk of death for both SxOA as well as rOA, 
although in this study knee SxOA was merely a subset of those with knee rOA, and did not 
distinguish between knee rOA alone and knee pain alone18. The conflicting results from 
these studies may reflect the differences in data sources and definitions of knee OA.
Knee pain is not a perfect marker of radiographic knee OA34, nor is radiographic knee OA a 
perfect marker for pain and disability35. There are other conditions which may lead to knee 
pain, including acute and overuse injuries, referred nerve pain and mechanical problems. 
Further, the definitions of knee rOA and knee pain used may affect the association between 
them. Our combined measure of knee rOA and knee pain allows us to assess the independent 
effects of both radiographic knee OA and pain on mortality. In addition, we adjusted for 
conditions that may affect knee pain, such as comorbidities and knee injury. Further, the 
impact of pain on mortality was found in a group of individuals who are at high risk of 
having other morbidity including CVD, cancer and diabetes which were accounted for in the 
analyses. Our results suggest that it is the symptoms of knee rOA, rather than the structural 
damage, that is associated with excess mortality.
While there is a large and growing body of literature on pain and mortality, the published 
results in general are restricted to non-site-specific chronic or widespread pain36. A possible 
explanation for the increase in mortality is that OA leads to a cycle of low physical activity, 
pain, disability, increased BMI and serious comorbidities such as diabetes and CVD37,38. 
Pain resulting from OA is a leading cause of disability, and its impact on mortality is 
supported by reports that OA accounts for a large portion of the years lived with disability 
and quality-adjusted life-years lost39,40. OA has also been shown to share many risk factors 
with CVD including age, obesity, hypertension and NSAID use, and it has been suggested 
that these conditions have overlapping causal pathways41. The inflammatory processes in 
certain comorbidities including CVD are known to be associated with increased risk of 
premature death, and recent reports suggest that those with OA may experience a low-grade 
chronic inflammation similar to CVD42. Further, symptomatic knee OA itself has been 
shown to increase risk of CVD43, although our results for CVD-specific mortality did not 
differ appreciably from those seen for all-cause mortality. While we were able to include 
many of these comorbid conditions in our models, we believe there is some aspect of knee 
pain that is not explained by other mortality-associated conditions accounted for in our study 
that warrants further study.
Obesity is known to have many deleterious effects on an individual’s health. In addition to 
increased risk of other comorbidities and disability, increasing BMI has been shown to be 
linearly associated with more pain, where those who are obese have been shown to have 
68% more pain than those who are not obese44. Further, those with a BMI>30 have also 
been shown to have greater risk of death than those with a BMI 18.5–2545. Our results are 
consistent with these reports; we found that among participants with a BMI≥30, individuals 
who also had knee pain and/or knee rOA had the greatest risks of both all-cause and CVD-
specific mortality.
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When we examined associations according to demographics, results suggested greater 
mortality for those with knee pain with or without knee rOA among women, Caucasians and 
those under the age of 65. Our results are similar to those of a study among women aged 45–
64 years of age in which those with knee pain or knee SxOA were at increased risk of 
death17. There are several plausible explanations for these observed results. Previous studies 
have shown that women with knee SxOA have higher rates of low function46 and 
depression47, both of which are associated with higher mortality rates48,49. Further, women 
in our study tended to have higher BMI than men. Our finding of greater mortality with knee 
pain/rOA among those who were younger may suggest a role for long-term psychological 
distress and disability. For example, it is possible that those who are younger may develop 
disability early on, leading to depression, reduced physical activity and increasing BMI 
resulting in the development of comorbidities at a younger age than expected.
Our study has several advantages. In contrast to previous studies that have measured knee 
OA at baseline and assessed its association with mortality thereafter, we utilized the richness 
of our dataset that included a baseline knee rOA/pain measurement and covariates with up to 
three follow-up assessments, yielding nearly 25 years follow-up. By using our longitudinal 
data we were able to study the effect of knee rOA/pain as it changes over time on mortality 
while also accounting for changing comorbidities, representing an improvement over 
traditional studies based on survival analyses relating all future survival to a risk factor and 
covariates assessed at a single moment in time14,15,17. Further strengths include that 
JoCoOA is a community-based longitudinal study with nearly 25 years of follow up that 
includes both men and AA, two sub-populations that have not been widely studied. Our 
assessment of mortality included the use of both NDI records as well as county vital records 
to determine whether a death occurred. Knee OA in our study was radiographically 
confirmed and read by a single radiologist, includes severity of disease and was measured at 
several different time points to account for possible change in rOA status over time. 
Furthermore, we adjusted our analyses for several well-known mortality-associated factors 
which are common in knee OA patients that warranted special attention in our study, 
including comorbidities and NSAID use. However, the possibility of residual confounding 
by unrecognized factors cannot be excluded. Finally, in order to assess the possibility of 
early deaths resulting from other causes, additional analyses excluding deaths in the first 
year of follow-up did not yield different results.
Limitations include that our measure of pain was somewhat crude in that it was defined as 
having at least mild knee pain most days. We also do not have a consistent measure of 
disability across follow-up assessments. Also, we do not have a precise date of rOA 
occurrence as it was measured at baseline, then at the three follow-up time periods of the 
study which varied in length. However, we used a Cox proportional hazards regression 
approach using a counting process which assumes the individual is continuously at risk of 
the event until the end of the follow-up period27. Our study has a long follow-up and as such 
is subject to incurring deaths due to natural causes and normal ageing. However, in our 
survival curves we see a clear separation of increasing deaths over time for those with knee 
rOA and/or knee pain even at longer observation times compared with those who have 
neither. Further, survival analyses take into account the timing of death and our results 
suggest that those with knee rOA and/or knee pain tend die sooner than those who do not. 
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We also experienced some study attrition over time. Our sensitivity analyses using baseline 
measures only as predictors of later mortality were similar to those using TVC. Since using 
baseline only information likely misses developing OA cases, we are likely underestimating 
the effect so we feel ours is a conservative approach.
Our results demonstrate an increased risk of mortality for individuals who had knee pain, 
alone or with knee rOA. These effects were particularly strong for those who were obese. 
Interventions should be targeted toward reducing pain, weight loss/maintenance and 
avoiding future comorbidities. Future studies should focus on defining pain phenotypes in 
knee rOA to identify subsets of individuals who are more likely to die in order to create 
more targeted interventions aimed at reducing pain and disability which have been linked to 
increased mortality.
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Fig. 1. 
Johnston County Osteoarthritis Study – Baseline Knee rOA participants.
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Fig. 2. 
Kaplan–Meier survival curves for mortality by baseline knee rOA and/or knee pain group, 
unadjusted (a) and adjusted for age and sex (b).
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Fig. 3. 
Adjusteda hazard ratios (HR) and 95% confidence intervals (CI) for the association between 
knee rOA and knee pain on all-cause mortality stratified by demographics and obesity, 
JoCoOA Study. aAdjusted for enrollment wave, age, sex, race, education, knee injury, 
cancer, non-steroidal anti-inflammatory drugs, hypertension, smoking, liver disease, alcohol 
use, depression, physical activity, obesity, diabetes, cardiovascular disease.
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Table I
Baseline demographic characteristics, JoCoOA Study
Baseline (n = 4182) n (%) or mean (SD; range)
Demographics
Enrollment wave
 T0 (1991–1997) 3136(75.0)
 T1^ (2003–2004) 1046 (25.0)
Baseline to follow-up (years) 14.7 (6.1; 0–24.6)
Age at visit (years) 61.0 (10.6; 45.0–93.6)
Female 2644 (63.2)
African American 1436 (34.3)
<High School Education 1500 (35.9)
BMI group
 <25 987 (23.6)
 ≥25.0 – <30 1516(36.3)
 ≥30.0 1668 (39.9)
Smoker 2063 (49.3)
Alcohol use 1986 (47.5)
<150 MVPA mins/week 3444 (82.4)
NSAID use 1439 (34.4)
Comorbidities
Cancer 50(1.2)
Cardiovascular disease 916(21.9)
Hypertension 1614(38.6)
Diabetes 551 (13.2)
Depression 538 (12.9)
Liver disease 68 (1.6)
Hip rOA 1169 (28.0)
Knee rOA/pain variables
No Knee rOA & No Knee Pain 1896 (45.3)
Knee rOA Alone (No Knee Pain) 434 (10.4)
Knee Pain Alone (No Knee rOA) 1129 (27.0)
Knee rOA & Knee Pain (SxOA) 723 (17.3)
FU=Follow-up.
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